Bevacizumab vs ranibizumab for neovascular age-related macular degeneration in Chinese patients

International Journal of Ophthalmology

Volumn 6, Issue 2, 2013, Pages 169-173

  Li, Jun ^a   Zhang, Han ^a   Sun, Peng ^a   Gu, Feng ^a   Liu, Zhe Li ^a  

^a CHINA MEDICAL UNIVERSITY   (China)

Author keywords

Age related macular degeneration; Bevacizumab (avastin); Choroidal neovascularization; Ranibizumab (lucentis)

Indexed keywords

EID: 84894573700     PISSN: 22223959     EISSN: 22274898     Source Type: Journal    
DOI: 10.3980/j.issn.2222-3959.2013.02.12     Document Type: Article

References (20)

1. Zou HD, Zhang X, Xu X., Wang FH, Zhang SJ. Age-related macular degeneration prevalence survey of Caojiadu street Jing'an district in Shanghai. ZhonghuaYanke Zhazhi. 2005; 41(1): 15-19.
2. Lou ZL, Chen G, Tang R. Age-related macular degeneration prevalence survey of agency personnel in Changsha city. Ophthalmol Res. 2008; 26(11): 822-823.
3. Ni Z. 1st edition. Shanghai: Shanghai Scientific Popularization Publishing House; 2002. Pathological anatomy and clinical of ophthalmology; pp. 281-282.
4. Sheng YJ. Advances in the treatment of age-related macular degeneration. J Clin Ophthalmol. 2004; 12(5): 471.
5. Bressler NM. Antiangiogenic approaches to aged-related macular degeneration today. Ophthalmology. 2009; 116(10 Suppl): S15-23.
6. Schouten JS, La Heij EC, Webers CA, Lundqvist IJ, Hendrikse F. A systematic review on the effect of bevacizumab in exudative age-related macular degeneration. Greafes Arch Clin Exp Ophthalmol. 2009; 247(1): 1-11.
7. Chakravarthy U, Harding SP, Rogers C.A., Downes SM, Lotery AJ, Wordsworth S, Reeves BC. Ranibizumab versus bevacizumab to treat neovascular age-related macular degeneration: one-year findings from the IVAN randomized trial. Ophthalmology. 2012; 119(7): 1399-1411.
8. Martin DF, Maguire MG, Fine S.L., Ying GS, Jaffe GJ, Grunwald JE, Toth C, Redford M., Ferris FL., 3rd Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results. Ophthalmology. 2012; 119(7): 1388-1398.
9. Krebs I, Schmetterer L, Boltz A., Told R, Vécsei-Marlovits V, Egger S, Schönherr U, Haas A, Ansari-Shahrezaei S, Binder S, MANTA Research Group A randomised double-masked trial comparing the visual outcome after treatment with ranibizumab or bevacizumab in patients with neovascular age-related macular degeneration. Br J Ophthalmol. 2013; 97(3): 266-271.
10. Hera R, Keramidas M, Peoc'h M, Mouillon M, Romanet JP, Feige JJ. Expression of VEGF and angiopoietins in subfoveal membranes from patients with age-related macular degeneration. Am J Ophthalmol. 2005; 139(4): 589-596.
11. Hornig C, Weich HA. Soluble VEGF receptors. Angiogenesis. 1999; 3(1): 33-39.
12. Tatar O, Adam A, Shinoda K., Stalmans P, Eckardt C, Lüke M, Bartz-Schmidt KU, Grisanti S. Expression of VEGF and PEDF in choroidal neovascular membranes following verteporfin photodynamic therapy. Am J Ophthalmol. 2006; 142(1): 95-104.
13. O'Shea JG. Response to replacing ranibizumab with bevacizumab on the Pharmaceutical Benefits Scheme: where does the current evidence leave us. Clin Exp Optom. 2012; 95(5): 541-543.
14. Senger DR, Van de Water L, Brown LF, Nagy JA, Yeo KT, Yeo TK, Berse B, Jackman RW, Dvorak AM, Dvorak HF. Vascular permeability factor (VPF, VEGF) in tumor biology. Cancer Metastasis Rev. 1993; 12(3-4): 303-324.
15. Kaiser PK, Brown DM, Zhang K, Hudson H.L., Holz FG, Shapiro H, Schneider S, Acharya NR. Angiographic and optical coherence tomographic results of the MARINA study of ranibizumb in neovascular age-related macular degeneration: subgroup analysis of first-year ANCHOR results. Am J Ophthalmol. 2007; 144(6): 850-857.
16. Holladay JT. Visual acuity measurements. J Cataract Refract Surg. 2004; 30(2): 287-290.
17. Joeres S, Heussen FM, Treziak T, Bopp S., Joussen AM. Bevacizumab (Avastin) treatment in patients with retinal angiomatous proliferation. Graefes Arch Clin Exp Ophthalmol. 2007; 245(11): 1597-1602.
18. Zhang H, Liu ZL, Sun P, Gu F. Intravitreal bevacizumab for treatment of subfoveal idiopathic choroidal neovascularization: results of a 1-year prospective trial. Am J Ophthalmol. 1712; 153(2): 300-306.
19. Raftery J, Clegg A, Jones J., Tan SC, Lotery A. Ranibizumab (Lucentis) versus bevacizumab (Avastin): modelling cost effectiveness. Br J Ophthalmol. 2007; 91(9): 1244-1246.
20. Abeysiri P, Johnston NR, Molteno AC. Price of bevacizumab for intravitreal injection in New Zealand. Clin Experiment Ophthalmol. 2010; 38(1): 38-84.